Table 1 Clinical characteristics of patients in NNRTI and PI group.
Characteristics | NNRTI N = 85 | PI N = 14 | P-value |
|---|---|---|---|
Age, mean ± SD, years | 40.6 ± 8.8 | 40.7 ± 10.9 | 0.776 |
Gender, number (%) | 0.993 | ||
Male | 38 (45) | 7 (50) | |
Female | 47 (55) | 7 (50) | |
Duration of HIV diagnosis, median (IQR), months | 65 (47–94) | 72 (47–109) | 0.788 |
History of OIs, number (%) | 10 (12) | 2 (14) | 0.992 |
HBV co-infection, number (%) | 6 (7) | 1 (7) | 0.957 |
HCV co-infection, number (%) | 3 (4) | 0 (0) | 0.451 |
NRTI backbone in HAART prior to TI, number (%) | 0.480 | ||
- Stavudine + lamivudine | 43 (51) | 7 (50) | |
- Zidovudine + lamivudine | 35 (41) | 5 (36) | |
- Zidovudine + didanosine | 4 (5) | 2 (14) | |
- Didanosine + lamivudine | 3 (3) | 0 (0) | |
Duration of HAART prior to TI, median (IQR), months | 46 (36–64) | 59 (37–76) | 0.968 |
Nadir CD4 cell count, median (IQR), cells/mm3 | 147 (57–215) | 217 (63–345) | 0.186 |
Baseline CD4 cell counts at TI, median (IQR), cells/mm3 | 530 (441–657) | 586 (381–747) | 0.924 |